Abstract:Background: Conducting traditional wet experiments to guide drug development is an expensive, time-consuming and risky process. Analyzing drug function and repositioning plays a key role in identifying new therapeutic potential of approved drugs and discovering therapeutic approaches for untreated diseases. Exploring drug-disease associations has far-reaching implications for identifying disease pathogenesis and treatment. However, reliable detection of drug-disease relationships via traditional methods is costly and slow. Therefore, investigations into computational methods for predicting drug-disease associations are currently needed. Results: This paper presents a novel drug-disease association prediction method, RAFGAE. First, RAFGAE integrates known associations between diseases and drugs into a bipartite network. Second, RAFGAE designs the Re_GAT framework, which includes multilayer graph attention networks (GATs) and two residual networks. The multilayer GATs are utilized for learning the node embeddings, which is achieved by aggregating information from multihop neighbors. The two residual networks are used to alleviate the deep network oversmoothing problem, and an attention mechanism is introduced to combine the node embeddings from different attention layers. Third, two graph autoencoders (GAEs) with collaborative training are constructed to simulate label propagation to predict potential associations. On this basis, free multiscale adversarial training (FMAT) is introduced. FMAT enhances node feature quality through small gradient adversarial perturbation iterations, improving the prediction performance. Finally, tenfold cross-validations on two benchmark datasets show that RAFGAE outperforms current methods. In addition, case studies have confirmed that RAFGAE can detect novel drug-disease associations. Conclusions: The comprehensive experimental results validate the utility and accuracy of RAFGAE. We believe that this method may serve as an excellent predictor for identifying unobserved disease-drug associations.

Multi-Label Classification with Dual Tail-Node Augmentation for Drug Repositioning.

Drug repositioning based on weighted local information augmented graph neural network

Boosting drug-disease association prediction for drug repositioning via dual-feature extraction and cross-dual-domain decoding

Self-supervised Learning for Label Sparsity in Computational Drug Repositioning

Graph Neural Network-Based Modeling with Subcategory Exploration for Drug Repositioning

A Flexible and Robust Multi-Source Learning Algorithm for Drug Repositioning

Prediction of drug–disease associations based on reinforcement symmetric metric learning and graph convolution network

Enhancing Drug Repositioning through Local Interactive Learning with Bilinear Attention Networks

Deep learning of multimodal networks with topological regularization for drug repositioning

Drug repositioning based on residual attention network and free multiscale adversarial training

Drug Repositioning by Multi-Aspect Heterogeneous Graph Contrastive Learning and Positive-Fusion Negative Sampling Strategy

Knowledge Graph Convolutional Network with Heuristic Search for Drug Repositioning

Drug repositioning based on the heterogeneous information fusion graph convolutional network

A weighted bilinear neural collaborative filtering approach for drug repositioning

Predicting Associations among Drugs, Targets and Diseases by Tensor Decomposition for Drug Repositioning

Drug-Disease Association Prediction Using Heterogeneous Networks for Computational Drug Repositioning

Drug repositioning with adaptive graph convolutional networks

Developing a Semi-Supervised Approach Using a PU-Learning-Based Data Augmentation Strategy for Multitarget Drug Discovery

Empowering Graph Neural Network-Based Computational Drug Repositioning with Large Language Model-Inferred Knowledge Representation

Drug Repositioning Based on the Enhanced Message Passing and Hypergraph Convolutional Networks